Figure 1
Figure 1. Effect of SB-559457 on the growth of primary human leukemia cells. (A) Chemical structure of SB-559457. Representative growth curves of primary leukemia cells from AML patients (B) inhibited by SB-559457 (SB) stimulation, or (C) uninhibited; (D) CML patients inhibited by SB-559457, or (E) uninhibited; and (F) ALL patients. Cells were cultured in suspension in medium alone (control), in medium supplemented with rhTpo (2.86μM) or SB-559457 (5μM), or in 0.05% DMSO alone, the final concentration of DMSO in 5μM SB-559457 solution. (G) Table summarizing the percentage decrease in cell number, compared with untreated control cells, of all samples exposed to SB-559457 or rhTpo. (H) Annexin V/PI staining of primary AML cells from a representative sample inhibited by exposure to SB-559457 (AML774), or uninhibited (AML710), compared with growth in rhTpo containing 0.05% DMSO. Samples were analyzed after 48 hours of exposure.

Effect of SB-559457 on the growth of primary human leukemia cells. (A) Chemical structure of SB-559457. Representative growth curves of primary leukemia cells from AML patients (B) inhibited by SB-559457 (SB) stimulation, or (C) uninhibited; (D) CML patients inhibited by SB-559457, or (E) uninhibited; and (F) ALL patients. Cells were cultured in suspension in medium alone (control), in medium supplemented with rhTpo (2.86μM) or SB-559457 (5μM), or in 0.05% DMSO alone, the final concentration of DMSO in 5μM SB-559457 solution. (G) Table summarizing the percentage decrease in cell number, compared with untreated control cells, of all samples exposed to SB-559457 or rhTpo. (H) Annexin V/PI staining of primary AML cells from a representative sample inhibited by exposure to SB-559457 (AML774), or uninhibited (AML710), compared with growth in rhTpo containing 0.05% DMSO. Samples were analyzed after 48 hours of exposure.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal